News and Trends 27 Jun 2023 GSK gonorrhea vaccine fast tracked The US Food and Drug Administration (FDA) has granted a Fast Track designation for GSK plc’s Neisseria gonorrhoeae investigational vaccine (NgG). The vaccine candidate is currently in an ongoing phase II trial and aims to demonstrate proof of concept by assessing the efficacy of the NgG vaccine in healthy adults, 18 to 50 years of […] June 27, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2022 Intravacc to develop intranasal gonorrhea vaccine with $14.6M NIH/NIAID contract Intravacc has been awarded a contract with base and options that may total US$14.6 million for the development of a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). The contract has been awarded by the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), Gonorrhea is a sexually […] October 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Startup Scout 7 Jul 2017 A Norwegian Biotech is Aiming at Permanently Removing HPV Skin Infections This week we’re traveling to Bergen, a beautiful coastal city in Norway surrounded by seven mountains, where a biotech called Cytovation is developing a brand new treatment for benign tumors caused by the human papillomavirus. Mission: Cytovation is developing what could be the first prescription treatment for cutaneous warts, which are a form of […] July 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jun 2017 Results are in for Europe’s First Biobanking Study on HPV Cervical Cancer The RAIDs consortium made its closing event last week. After 4.5 years of studies, it has managed to change our appreciation of HPV cervical cancer towards building intelligent targeted therapy designs. Every year in Europe, 16,000 women die from cervical cancer and another 34,000 are newly diagnosed, which makes it the second most frequent form […] June 14, 2017 - 5 minutesmins - By Timothé Cynober Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2016 €4M Grant for a Cancer Vaccine that could Bench its Competitors Hookipa just secured a huge grant from the Austrian government. The plan is to develop the strongest HPV vaccine ever and claim its place in the €2B head and neck cancer market. Hookipa, one of the hottest Biotechs in Vienna, develops vaccines based on a new class of viral vectors. Its platform has impressed the public sector and secured €4.16M from the Austrian […] October 18, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2016 Transgene teams up with big Players against HPV Head and Neck Cancer Transgene is partnering with Merck and Pfizer to develop a combined therapy for head and neck cancer squamous cell carcinoma (HNSCC) caused by human papiloma virus (HPV) infections. A successful outcome will let the team access a €2B market niche. Transgene has been struggling for a while: last year it had to fire 40% of its workforce […] October 12, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email